Cross-Border Strategy
US + Latin America Cardiovascular Trial Strategy — A Sponsor's Cross-Border Guide
This guide is for sponsor clinical-operations leads and biotech founders evaluating whether a hybrid design fits their cardiovascular trial. It draws on a decade of running first-in-human and pivotal cardiovascular work across both regions through Amavita Research (US) and bioaccess® (Latin America).
When a hybrid US + Latin America design makes sense
Cross-border designs aren't right for every trial. They make sense when at least two of these conditions hold:
- You need to reach first-patient-enrolled faster than US-only sites can deliver. Start-up and regulatory review timelines vary by country, submission pathway, dossier completeness and authority requests. We provide study-specific estimates during feasibility.
- You need ethnic and demographic diversity that US-only enrollment can't easily produce. FDA's Diversity Action Plans Final Guidance (June 2024) puts pressure on sponsors to enroll cohorts that reflect the disease's actual prevalence patterns. Latin America cohorts naturally produce Hispanic/Latino patient data that US sites often struggle to recruit. See our companion guide on FDA DAP and cardiovascular site selection.
- You're capital-sensitive and the per-patient cost differential is meaningful at your sample size. Per-patient costs vary by country and protocol; compare site budgets during feasibility.
- You're running a first-in-human protocol where a Latin American regulatory pathway fits the protocol.
- You need a Phase 1 or feasibility cohort fast, then expand to US pivotal. A staged design — Phase 1/early Phase 2 in Latin America, pivotal in US — is one of the most efficient capital structures available for novel cardiovascular treatments.
When it doesn't make sense
Be honest about when cross-border isn't the right answer:
- Your trial is a registry or Phase 4 commitment study and the FDA wants US-population data specifically
- Your protocol requires US-only labeling considerations that won't accept non-US data
- Your investigational product can't be reliably shipped to the LATAM site (cold-chain failures are real)
- Your sponsor team doesn't have bandwidth to coordinate two regional teams, and you don't want to hire a CRO to bridge
If any of these hold, US-only is the right call.
The five strategic pillars of cross-border execution
Pillar 1: Regulatory pathway selection
Each Latin American country has a different regulatory pathway, with different speeds, different documentation expectations, and different patient-protection frameworks. The key options for cardiovascular work:
- Colombia (INVIMA): Strong cardiovascular ecosystem in Bogotá and Medellín. Strong Spanish-language informed-consent infrastructure. Established for first-in-human work.
- Argentina (ANMAT): Mature regulatory framework, well-respected by global agencies.
- Chile (ISP): Excellent for cardiology and oncology. Strong reputation for trial conduct quality.
- Mexico (COFEPRIS): Confirm patient access and regulatory timelines for the protocol.
Start-up and regulatory review timelines vary by country, submission pathway, dossier completeness and authority requests. We provide study-specific estimates during feasibility.
A bridging CRO with local regulatory experience does the country selection based on your protocol's specific needs (indication, device vs. drug, FIH vs. pivotal).
Pillar 2: Protocol harmonization
The single protocol runs in both regions. Key harmonization decisions:
- Inclusion/exclusion criteria — must be identical or differ in ways pre-specified in the statistical analysis plan
- Primary and secondary endpoints — identical, measured the same way at both regions
- Data capture standards — same eCRF, same central labs where feasible, same imaging core lab
- Statistical analysis plan — pre-specifies how regional data will be pooled, what pre-specified subgroup analyses will be done, how heterogeneity will be addressed
The harmonization work happens upfront. Once the protocol is locked, regional teams execute against the same template.
Pillar 3: PI selection and training
Latin America cardiology has produced world-class investigators, but trial conduct quality varies by site. Cross-border CROs filter for sites with:
- Active English-language documentation capability
- ICH-GCP training current and verifiable
- Prior FDA inspection-ready trial history
- PI continuity (same problem as US sites — networks vs. independent practices)
- Active patient flow in the indication (not database-recruited)
The PIs at each region attend the same investigator meeting. Same protocol training, same source-document expectations, same monitoring cadence.
Pillar 4: Operational integration
The two regional arms need to feel like one trial to the sponsor. That requires:
- Single data lake — both regions feed the same eCRF / data management system
- Coordinated monitoring — same CRA standards, monitoring frequency, query response SLAs
- Coordinated drug supply — IP shipping logistics planned at protocol design, not retrofit
- Coordinated safety reporting — adverse events from both regions flow into the same safety database, reviewed by the same DSMB
- Single sponsor-facing point of contact — typically the lead CRO or, in our case, the bioaccess®/Amavita Research integrated team
When this integration is loose, the trial functionally splits into two trials. When it's tight, it operates as one.
Pillar 5: Data analysis and FDA submission strategy
The statistical analysis plan should pre-specify:
- Pooled analysis as the primary inferential approach
- Pre-specified regional subgroup analyses
- Tests of heterogeneity (with thresholds)
- Sensitivity analyses excluding either region
When properly designed and pre-specified, FDA reviewers accept pooled US + Latin America data routinely for cardiovascular indications. The cases where they push back are when the analysis plan wasn't pre-specified, when regional differences in disease background or standard of care weren't documented, or when the LATAM sites' trial conduct quality wasn't documented to FDA standards.
This is solvable with planning. It's not solvable in cleanup.
A practical example: hypertension trial design
Suppose you're running a Phase 2 hypertension trial for a novel RNAi therapeutic. You want N=300, diverse cohort, FPE within 6 months of contract execution.
US-only path: US sites only. Budget and enrollment timeline depend on the protocol and site performance. Hispanic/Latino representation depends on site selection.
US + LATAM hybrid path: US sites (including Amavita Research) plus LATAM sites (for example Colombia, Chile, Argentina). Budget and timeline are estimated per study during feasibility. Hispanic/Latino representation is typically higher.
Compare both paths with study-specific estimates.
How Amavita Research and bioaccess® work together
Amavita Research is the US arm — an independent investigator-led cardiovascular trial site in North Miami Beach, FL, embedded inside amavita Heart and Vascular Health®. bioaccess® is the Latin America arm — a first-in-human CRO with operations across Colombia, Argentina, and other regional markets.
The same leadership team coordinates both. Julio G. Martinez-Clark is CEO of bioaccess® and Chief Executive Officer (CEO) of Amavita Research. Dr. Pedro Martinez-Clark, MD, FACC is a Principal Investigator at Amavita and a long-tenured cardiovascular research veteran with deep Latin America regulatory experience.
For sponsors, this means:
- A single contracting party for protocols that span both regions
- A single point of contact for protocol amendments, safety reporting, and operational decisions
- A coordinated data flow without third-party CRO handoffs between regions
- US trial conduct quality (IAOCR GCSA, ICH-GCP E6(R3)) at the US arm; equivalent quality framework at the LATAM arm
Published bioaccess® FIH client outcomes
Publicly-disclosed bioaccess® FIH client deliveries (as stated by bioaccess®) include:
- Axoft — 4 brain-computer interface implants in 2.5 years
- PAVmed — CarpX™ device with FDA Breakthrough Device Designation using LATAM clinical data
- Avantec Vascular — Sangria™ venous remodeling system FIH in El Salvador
bioaccess provides CRO services in the Americas. Its project experience is separate from Amavita Research's site experience.
Across the full portfolio, bioaccess® reports 50+ delivered FIH programs since 2010 (from a base of hundreds of consulted companies) across 19 Latin American and Caribbean markets. Sponsors running US + Latin America hybrid cardiovascular trial designs can engage the integrated Amavita Research + bioaccess® relationship through a single counterpart.
Learn more about the sister-organization relationship →
Practical next steps
If you're evaluating a hybrid US + Latin America design for a cardiovascular protocol:
- Send a protocol synopsis to /contact-sponsor. We respond promptly with regional feasibility, indicative timelines, and cost ranges.
- Schedule a 30-minute strategy call with Julio or with one of our regional leads to walk through your specific protocol and design.
- If there's a fit, we move to CDA for the Amavita US arm and for the bioaccess® LATAM arms.
You can also explore the full Amavita Research site at amavitaresearch.com and the bioaccess® site at bioaccessla.com.
About the author: Julio G. Martinez-Clark is Chief Executive Officer (CEO) of Amavita Research and CEO of bioaccess®, the first-in-human CRO for the Americas. He has spent over a decade structuring cross-border cardiovascular trial designs for US and global sponsors. Connect on LinkedIn or read more at juliomartinezclark.com.
Next step
Considering a US + Latin America design for your cardiovascular trial?
Send a protocol synopsis. 48-business-hour response with regional feasibility, indicative timelines, and cost ranges across both arms.